After Wells Fargo and BMO Capital assigned a Buy rating to Intercept Pharma in the last month, the company received another Buy, this time from JMP Securities. Analyst Liisa Bayko maintained a Buy rating on Intercept Pharma (NASDAQ: ICPT) today and set a price target of $200. The company’s shares closed last Friday at $141.77.
According to TipRanks.com, Bayko is a 5-star analyst with an average return of 18.3% and a 51.1% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Anthera Pharmaceuticals, and Conatus Pharmaceuticals.
Currently, the analyst consensus on Intercept Pharma is Moderate Buy and the average price target is $213.67, representing a 50.7% upside
. In a report released today, Cowen & Co. also maintained a Buy rating on the stock with a $215 price target.
Based on Intercept Pharma`s latest earnings report from March 31, the company posted quarterly revenue of $445k and quarterly net profit of -$126.7M. In comparison, last year the company earned revenue of $1.45M and had a net profit of -$39.39M.
Unlike JMP Securities` latest rating, based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is neutral on the stock. Earlier this month, Lisa Bright, a the Chief Commercial & Corporate Affairs Officer of ICPT sold 251 shares for a total of $34,510.
Intercept Pharmaceuticals, Inc. is a development stage biopharmaceutical company. It focuses on the discovering, developing and commercializing of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. It develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase II clinical trial for the treatment of alcoholic hepatitis; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea. Intercept Pharmaceuticals was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
The post Intercept Pharma Received its Third Buy in a Row appeared first on Markets.co.